Concord Medical Services

CCM

시가총액 US$1576만

SAN FRANCISCO--(BUSINESS WIRE)--ComplianceCow, an agentic automation platform for enterprise security GRC teams, will host a live webinar on June 22, 2026 demonstrating how Generative AI transforms natural language inputs into deterministic, auditable Continuous Controls Monitoring (CCM) 3.0 controls inside ServiceNow IRM. The session, titled From Prompt to Production: Building Automated CCM 3.0 Controls with Generative AI in ServiceNow IRM, runs from 1:30 to 2:00 pm ET and is open to complianc.

TYSONS, Va.--(BUSINESS WIRE)--RegScale, the AI-powered continuous controls monitoring (CCM) platform, today announced it has achieved ISO 27001 certification in under 30 days using its own Continuous Controls Monitoring (CCM) platform. For most organizations pursuing certification through manual processes, the journey runs around six months. RegScale's result demonstrates what becomes possible when compliance runs continuously: certification is a byproduct of the program, not a project of its o.

BEIJING, April 29, 2026 /PRNewswire/ -- Concord Medical Services Holdings Limited ("Concord Medical" or the "Company") (NYSE: CCM), a healthcare provider specialized in cancer treatment, research, education and prevention in China, today announced that it filed its annual report on Form 20-F for the fiscal year ended December 31, 2025 (the "Annual Report") with the U.S. Securities and Exchange Commission ("SEC"). An electronic copy of the Annual Report can be accessed on Concord Medical's investor relations website at  http://ir.ccm.cn  and on the SEC's website at www.sec.gov.

BEIJING , Dec. 2, 2025 /PRNewswire/ -- Concord Medical Services Holdings Limited ("Concord Medical" or the "Company") (NYSE: CCM), a healthcare provider specialized in cancer treatment, research, education and prevention in China, today announced that it will hold its 2025 annual general meeting of shareholders (the "Meeting") on December 29, 2025, at 10:00 a.m. (Beijing Time).

As of Oct. 16, 2025, two stocks in the health care sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions.

BEIJING , Sept. 26, 2025 /PRNewswire/ -- Concord Medical Services Holdings Limited ("Concord Medical" or the "Company") (NYSE: CCM), a healthcare provider specialized in cancer treatment, research, education and prevention in China, today announced its unaudited consolidated financial results for the six months ended June 30, 2025[1].

BEIJING , July 14, 2025 /PRNewswire/ -- Concord Healthcare Group Co., Ltd. ("Concord Healthcare"), a subsidiary of Concord Medical Services Holdings Limited (the "Company") (NYSE: CCM), which subsidiary is listed on the Main Board of The Stock Exchange of Hong Kong Limited (the "HKSE") under the stock code 2453.HK, announced that on July 11, 2025, Guangzhou Concord Cancer Center, a subsidiary of Concord Healthcare, successfully completed the first proton therapy treatment in China for a patient with choroidal malignant melanoma.

BEIJING , May 29, 2025 /PRNewswire/ -- Concord Healthcare Group Co., Ltd. ("Concord Healthcare"), a subsidiary of Concord Medical Services Holdings Limited (the "Company") (NYSE: CCM), which subsidiary is listed on the Main Board of The Stock Exchange of Hong Kong Limited (the "HKSE") under the stock code 2453.HK, announced that Concord Healthcare had made important progress in precise tumor diagnosis and treatment technology.

BEIJING , April 25, 2025 /PRNewswire/ -- Concord Medical Services Holdings Limited ("Concord Medical" or the "Company") (NYSE: CCM), a healthcare provider specialized in cancer treatment, research, education and prevention in China, today announced that it filed its annual report on Form 20-F for the fiscal year ended December 31, 2024 (the "Annual Report") with the U.S. Securities and Exchange Commission. An electronic copy of the Annual Report can be accessed on Concord Medical's investor relations website at http://ir.ccm.cn and on the SEC's website at www.sec.gov.

BEIJING , Jan. 6, 2025 /PRNewswire/ -- Concord Medical Services Holdings Limited ("Concord Medical" or the "Company") (NYSE: CCM), a healthcare provider specialized in cancer treatment, research, education and prevention in China, today announced that it held its 2024 annual general meeting of shareholders on December 27, 2024. At the meeting, the shareholders resolved by special resolution that amended and replaced the Fourth Memorandum and Articles of Association of the Company then in effect by the adoption of the Fifth Amended and Restated Memorandum and Articles of Association.